TrialFrontiers in immunology2022

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE).

Hongtao Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.